<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">The antimicrobial effects of the EOs were evaluated against Gram-positive bacteria 
 <italic>Bacillus cereus</italic> ATCC 11778, 
 <italic>Enterococcus faecalis</italic> (clinical isolate), 
 <italic>Enterococcus faecium</italic> (clinical isolate), two strains of 
 <italic>Staphylococcus aureus</italic> (ATCC 6538 and one food spoilage isolate), and 
 <italic>Listeria monocytogenes</italic> NCTC 11994; Gram-negative bacteria: 
 <italic>Escherichia coli</italic> ATCC 25922, 
 <italic>Klebsiella pneumoniae</italic> (clinical isolate), two strains of 
 <italic>Salmonella abony</italic> (ATCC 6017 and one clinical isolate), 
 <italic>Shigella flexneri</italic> (clinical isolate), two strains of 
 <italic>Pseudomonas aeruginosa</italic> (ATCC 27853 and one clinical isolate), and a food spoilage isolate of 
 <italic>Pseudomonas fluorescens</italic>. 
 <italic>Proteus mirabilis</italic> (clinical isolate), and 
 <italic>Proteus vulgaris</italic> (clinical isolate); yeasts: two strains of 
 <italic>Candida albicans</italic> (ATCC 10231 and one clinical isolate), 
 <italic>C. glabrata</italic> (clinical isolate) and 
 <italic>C. tropicalis</italic> (clinical isolate). The clinical isolates from bacteria were kindly provided by the Department of Microbiology and Immunology at the Medical University of Plovdiv, and the yeast isolates were kindly provided by the National Referent Laboratory of Mycology at the National Center of Infectious and Parasitic Diseases in Sofia, Bulgaria.
</p>
